EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP